drugset / Trial / NCT00842998
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion biological study will assess factors correlated with sensitivity or resistance to either one of the compounds
Timeline
- Start
- 2009-02
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 2 mg/kg | Intravenous |